Neuromuscular gene panel provides comprehensive analysis
Answers from the Lab
Neuromuscular disorder is an umbrella term covering many conditions linked to multiple genetic mutations. In this test-specific episode of the "Answers From the Lab" podcast, Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs precise diagnosis for optimal patient care.
"The neuromuscular gene panel offers a more comprehensive phenotype analysis than other tests on the market," Dr. Niu says. "We analyze 217 genes — the most complete list of neuromuscular genes and their mutations — to detect single nucleotide variants, insertion deletions, and copy number events."
The phenotype-based test design draws on the expertise of Mayo Clinic neurologists.
"Our clinical experience has highlighted the range of genotype-phenotype correlation," Dr. Klein says. "The completeness and accuracy of this panel allows us to avoid mistakes in our diagnoses and guide patients to treatment options that weren't available in the past."
Listen to learn more about Mayo Clinic Laboratories' updated neuromuscular gene panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Establishing a molecular diagnosis for patients with a neuromuscular disorder.
Identifying variants within genes known to be associated with neuromuscular disorders allowing for predictive testing of at-risk family members.
Additional Information: If a cord blood specimen is received, MATCC / Maternal Cell Contamination, Molecular Analysis, Varies will be performed at an additional charge; maternal blood sample is required.
Analytic time: 28 to 42 days
Days performed: Varies
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.